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Introduction {#sec005}
============

In ultrasonic perfusion imaging (UPI), different methods are used to display parenchymal microvascular blood supply \[[@pone.0220171.ref001]\]. Two basic approaches are commonly applied in clinical settings. The bolus-kinetic approach analyses time-intensity curves that are derived in specific regions of interest (ROI) after a bolus injection of a standardized dose of contrast enhancer. The refill-kinetic approach additionally analyses noise alterations in specific ROIs. However, validation starts after the accomplishment of a steady state of contrast enhancer concentration in the blood pool with the destruction of contrast enhancer by the application of high mechanical index (MI) energy flashes followed by low MI sequences depicting the characteristic of replenishment ("refilling") of contrast enhancer. In stroke patients, various reports have consistently proven the ability of characterizing ischemic areas. A reliable discrimination of critically hypoperfuzed and irreversibly ischemic areas (penumbra and core) has only been proposed for the high MI bolus-kinetics (HighMiB) approach \[[@pone.0220171.ref002]--[@pone.0220171.ref004]\].

Using two well-described specific UPI protocols, this study was designed to validate the potential of detecting the degree of impaired cerebral parenchymal perfusion. HighMiB with a bilateral approach and unilateral low MI refill-kinetics (LowMiR) were tested against timely matched perfusion-weighted MRI or perfusion CT in a group of patients with acute infarction caused by middle cerebral artery occlusion as seen in the preceding CTA or MRA eligible for interventional therapy.

Materials and methods {#sec006}
=====================

Patients {#sec007}
--------

Patients with acute ischemic stroke admitted to the Stroke Center of the Inselspital, University Hospital Bern, Switzerland, between October 2012 and March 2014 who were scheduled for mechanical thrombectomy were enrolled in the study if an experienced sonographer (JE, MO, RR) was on duty. Enrollment was performed immediately after perfusion CT (CTP) or MR perfusion (MRP) imaging. UPI was performed after ultrasonic depiction of both MCAs in the angio-suite during the preparation for the interventional procedure and was not allowed to delay any therapeutic intervention. The sonographer was blinded to CT or MR perfusion results at the time of the examination. Patients with insufficient temporal bone window defined by the failure to depict standard landmarks were excluded \[[@pone.0220171.ref002]\]. Age below 18 and severe heart, lung and kidney diseases were defined as contraindication according to the regulatory rules of the echo-contrast agent SonoVue (Bracco Diagnostics, Milan, Italy). Severity of stroke was documented by use of the National Institutes of Health Stroke Scale on admission. The protocol for collecting data was in accordance with the 1996 revision (Somerset West, RSA) of the Declaration of Helsinki (1964) and was approved by the local ethics committee (Kantonale Ethikkommission Bern, No. KEK 179/12). Informed consent was obtained in all patients in a two-step procedure: (i) in the acute phase of the study, the patients´ relatives approved the participation of the patient in the study; (ii) in the follow-up phase, up to three months after stroke, the patients themselves approved, or, if aphasia was still present, the approval was obtained from the legal representative of the patient retrospectively. Written consent was mandatory under all circumstances.

Ultrasound perfusion imaging {#sec008}
----------------------------

All examinations were performed using a Philips iU22 ultrasound machine (Philips Healthcare, Andover, MA, USA) equipped with a 1--5 MHz dynamic sector array (S5-1). The field-of-view (FOV) was set to an imaging depth of 150 mm in a sector angle of 90°. Peak systolic velocities (PSV) of both MCA were depicted. Imaging plane was then tilted to the diencephalic plane as described before \[[@pone.0220171.ref002]\], where the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the MCA territory can be visualized well without major vessels producing artefacts.

HighMiB was defined as described before \[[@pone.0220171.ref002],[@pone.0220171.ref004]\]. To enable evaluation of cortical ROIs, the probe was held contralaterally to the suspected symptomatic hemisphere. Data acquisition was obtained in of 45second periods immediately after iv injection of a 2.0 ml bolus of the contrast enhancer SonoVue (Bracco International, Milan, Italy) using an MI setting of 1.34 and a frame rate of 5 Hz. Data were then analyzed off-line using VueBox software version 4.3 (Bracco Imaging, Geneva, Switzerland) by fitting a bolus-model function and extracting specific parameters of perfusion \[[@pone.0220171.ref005]\]. Both region-wise analysis and that of calculated parameter images for the time-to-peak intensity (TPI) were performed \[[@pone.0220171.ref006]\]. ROI-wise analyses were performed in pre-specified ROIs with the analyses of unaffected hemisphere to achieve an intra-individual reference value for the depth independent time associated parameter TPI \[[@pone.0220171.ref006]\]. Evaluation of the affected hemisphere was performed by extracting these parameters in 10 pre-specified ROIs, including three cortical areas as well as three areas of the white matter, the basal ganglia (head of caudate nucleus and lentiform nucleus), and the thalamus. A TPI of \>3 s was chosen as cut-off value for delayed perfusion (compare \[[@pone.0220171.ref004]\]), no perfusion was defined by missing rise of the time-intensity curve.

LowMiR was performed as described elsewhere \[[@pone.0220171.ref007]\] with depth of examination limited to 10cm and with the exception of extracting more specific parameters out of similarly placed ROIs in accordance to the high MI approach. This was done in order to gain as much as possible "spatial resolution". Two data sets were taken without time delay from either hemisphere to enable the comparison of affected and unaffected areas. After bolus application of 2.5 ml SonoVue, data acquisition was started and the visualization of the contrast arrival using an MI of 0.17 with a frame rate of 16 Hz was gained. Immediately after that, nine flashes of high MI (0.87) were applied to destroy the microbubbles in the scanning plane, followed by 20 s of further data acquisition with the low MI settings for the detection of replenishment. Off line analysis was performed as described above by comparing the A and β values of the fitted replenishment-model and the product of Axβ in 7 pre-specified ROIs (caudate nucleus, anterior and posterior thalamus, lentiform nucleus, anterior / middle / posterior MCA white matter) using the VueBox software, version 4.3 (Bracco Imaging, Geneva, Switzerland). Insufficient temporal bone window was assumed once the low MI Bolus examination of the unaffected hemisphere did not display any signal.

Magnetic resonance and computed tomography perfusion imaging (MRP/CTP) studies {#sec009}
------------------------------------------------------------------------------

CT/MRI perfusion was obtained in accordance to the standard-of-care protocol of the time and data were analyzed by three different investigators (RW, MO, RR) using a Food and Drug Administration (FDA) approved software (OleaSphere V2.3, OLEA Medical SA, La CiotatFrance). Analysis was performed using predefined circular ROIs of 50 mm^2^ (head of caudate nucleus, lentiform nucleus, anterior and posterior thalamus) and 200 mm^2^ (anterior, middle, and posterior MCA white matter as well as anterior, middle, and posterior MCA gray matter). For the quantification algorithm, the depicted ROIs were placed on a standard diencephalic plane as described previously \[[@pone.0220171.ref004]\], i.e. all ROIs are analyzed on the identical axial plane for both hemispheres. We defined the diencephalic plane by identification of lateral ventricles with their anterior and posterior horns, the plane crossing the third ventricle in its upper region surrounded by the thalamic and basal ganglia structures. The placement of the ROIs was performed after consensus of at least two of the three investigators (RW, MO, RR).

Time to peak (TTP) measurements of the ROIs on MRIs and CTs were extracted identically to the ROIs of the UPI investigation. The individual median of nonaffected contralateral ROIs served as reference and the cutoff threshold used was a delay of 4 s \[[@pone.0220171.ref004]\]. Categorization was done with a) "normal perfusion" = TTP within 4 s; b) "hypoperfusion" = TTP delay of \>4 s, c) "no perfusion" = no rise of the time--intensity curve detectable. For the categorization of relative cerebral blood flow (rCBF) and relative cerebral blood volume (rCBV) thresholds were used as described before \[[@pone.0220171.ref008]\], i.e. 0.67 and 0.74 respectively.

Analyses and statistical evaluation {#sec010}
-----------------------------------

Descriptive statistics (mean, median, s.d. and percentiles) were applied for all UPI parameters (TPI for HighMiB and A, β, and Axβ for LowMiR) and perfusion MRI/CT parameter (TTP, MTT, rCBF and rCBV). Normal distribution was shown for the UPI parameters TPI and for the MRP/CTP parameter MTT and rCBF, whereas all the other parameter had no normal distribution. Statistical analyses were done using the SPSS Statistics Software (Version 22, Chicago, IL, USA).

Further evaluation was three-split:

1.  First, correlation of LowMiR values of rise rate (β) and plateau (Axβ) with MRP/CTP values of rCBV and rCBF was tested by using a Bland-Altman plot.

2.  Second, correlation of HighMiB values and MRP/CTP has already been described and partially been published elsewhere \[[@pone.0220171.ref004]\]; the HighMiB data of the 16 patients have been compared to MRP/CTP. Analysis of receiver operating characteristics proved a high sensitivity of HighMiB in the diagnosis of hypo perfused (AUC = 0.917; p \<0.001) and non-perfused (AUC = 0.830; p \<0.001) tissue in comparison with CTP and MRP. Therefore, analyses have not been repeated here. Here, we retested these values by plotting the individual TTP delay of each ROI of the affected hemispheres as to the mean of ROIs of the same patients with the according MRP/CTP values.

3.  Third, LowMiR (β and Axβ) and HighMiB (TTP delay) parameters of those six patients in which both methods could be successfully performed were dichotomized according to the previously described threshold values of pathological perfusion for the according parameters. These were for β \< 0.76, for Axβ \< 1.91 in LowMiR \[[@pone.0220171.ref007]\], and for TTP \> 3s in HighMiB \[[@pone.0220171.ref004]\]. ROIs were then categorized in a fourfold table depending on the accordingly dichotomized parameter of rCBF/rCBV or TTP in MRP/CTP with a threshold of 0.67/0.74 or 4 s for direct qualitative comparison of both UPI methods with CT-/MRP by displaying positive and negative predictive values of the detection of any perfusion impairment. Only those ROIs were chosen, which were eligible for analysis both with HighMiB and LowMiR, i.e. cortical ROIs were not included.

Results {#sec011}
=======

Study population {#sec012}
----------------

Thirty-one consecutive patients were included (see [Table 1](#pone.0220171.t001){ref-type="table"}). Six patients (19.4%) did not display a sufficient temporal bone window. In three patients, examiner driven shortcomings led to illegible ultrasound examinations. In two patients, the perfusion weighted standard examination (CT or MRI) was not eligible. Therefore, data of only 20 patients (64.5%) with at least one sufficient temporal bone window were eligible for further analyses. In 16 patients (51.6%), HighMiB was technically successful; in 10 patients (32.3%), LowMiR was eligible, in two of which only the non-affected side was eligible. In six (19.4%) out of the remaining eight patients, both HighMiB and LowMiR were successful (see [Fig 1](#pone.0220171.g001){ref-type="fig"}).

10.1371/journal.pone.0220171.t001

###### Patients´ demographic data.

![](pone.0220171.t001){#pone.0220171.t001g}

  Consecutive patient No.   Occluded branch   Age      Sex        NIHSS admission   SOT \[min\]   HighMiB   LowMiR   CTP/MRP
  ------------------------- ----------------- -------- ---------- ----------------- ------------- --------- -------- ---------
  **1**                     rM1               76       F          15                123           Y         N        MRP
  **2**                     rM1               93       M          17                63            N         N        CTP
  **3**                     lICA              72       F          6                 245           Y         N        MRP
  **4**                     lICA              81       M          17                55            Y         N        MRP
  **5**                     lM1               90       F          20                45            N         N        CTP
  **6**                     rM1               75       F          8                 90            Y         N        MRP
  **7**                     rM1               80       F          4                 278           Y         N        CTP
  **8**                     rICA, rM1         70       M          13                85            Y         Y        MRP
  **9**                     lM1               86       M          24                50            Y         Y        CTP
  **10**                    rICA, rM1         79       F          17                40            N         N        CTP
  **11**                    lM1               81       M          28                90            N         N        CTP
  **12**                    rM1               78       F          11                255           Y         N        MRP
  **13**                    lICA-T            65       F          21                289           N         N        CTP
  **14**                    rM2               70       M          8                 152           N         N        MRP
  **15**                    rM1               85       F          7                 100           Y         N        MRP
  **16**                    rM1               80       F          15                53            N         N        MRP
  **17**                    lM2               65       M          3                 77            Y         N        MRP
  **18**                    rM1               63       F          7                 WUS           N         N        MRP
  **19**                    lICA-T            49       F          19                WUS           N         N        CTP
  **20**                    rICA              80       F          14                195           Y         N        MRP
  **21**                    lM2               68       F          11                WUS           N         N        MRP
  **22**                    rM1               56       M          7                 74            N         Y        CTP
  **23**                    rM1               75       M          16                166           N         Y        CTP
  **24**                    lM2               73       F          7                 52            Y         N        MRP
  **25**                    rM2               74       F          5                 121           Y         Y        MRP
  **26**                    rICA, rM3         74       M          25                132           N         N        MRP
  **27**                    rICA, rM1         80       F          19                256           N         N        CTP
  **28**                    lM4               76       M          7                 192           Y         Y        MRP
  **29**                    lM3               74       M          3                 63            Y         Y        MRP
  **30**                    rM1               36       M          3                 218           N         N        CTP
  **31**                    lM1               79       M          20                46            Y         Y        MRP
  **Mean/sum**                                **74**   **17 F**   **13**            **129**       **16**    **8**    
  **SD**                                      **11**              **7**             **81**                           

Demographic data of patients included in the study. Side of occlusion: r = right, l = left. Occluded vessel: M = middle cerebral artery segments 1--4; ICA = internal carotid artery; ICA-T = t-occlusion. SOT = symptom to onset time (if known). WUS = wake up stroke (if not known). Kinetics: HighMiB = high mechanical index bolus, LowMiR = low mechanical index refill. Ultrasound perfusion examination: Y = successful, N = not successful. Mode of standard perfusion imaging: CTP = CT perfusion, MRP = MR perfusion.

![Flow of patients´ recruitment.](pone.0220171.g001){#pone.0220171.g001}

Mean age of the 31 patients was 74 yrs (±11) with 17 female patients and with 3 \"wakeup strokes\" with unknown symptom onset and a mean \"symptom to onset time\" (SOT) of 129 min (±81) in the other 28 patients with a mean NIHSS score of 13 (±7). About half of the patients (except pat. no. 3,5,6,8,10,11--13,16,18--22,30) had running systemic thrombolysis with a delay between symptom onset and start of thrombolysis of 157 min (±49). The delay between either MRP or CTP to actual start of UPI was 58 min (±36). Side effects of the ultrasound contrast enhancer were detected in no patient.

In the 16 patients with successful HighMiB (age 77±11 yrs, 9 female, SOT 127±80 min, NIHSS score 10±6), 14 MRP and 2 CTP exams were undertaken before UPI. Eight patients had right-sided stroke with mostly proximal occlusion in the M1 segment in 44%, ICA occlusion in 25%, and M2/3/4 occlusion in 19/6/6%, respectively.

In the eight patients with successful LowMiR (age 74±9 yrs, 1 female, SOT 100±55 min, NIHSS score 12±8), five MRP and three CTP exams were undertaken before UPI. Three patients had right-sided stroke with mostly proximal occlusion in the M1 segment in 4/8, and ICA as well as M2/3/4 occlusion in 1/8.

In the six patients with both successful LowMiR and HighMiB (age 77±6 yrs, 1 female, SOT 93±56 min, NIHSS score 12±9), five MRP and one CTP exams were undertaken before UPI. Two patients had right-sided stroke with most proximal occlusion in the M1 segment in three patients, and ICA as well as M2/3/4 occlusion in one patient.

Perfusion deficits as defined by reference standard {#sec013}
---------------------------------------------------

For data values of perfusion imaging modalities see Tables [2](#pone.0220171.t002){ref-type="table"}--[4](#pone.0220171.t004){ref-type="table"}. Perfusion deficits in those 16 patients eligible for HighMiB were detected in MRP/CTP in 59/160 (39%) ROIs with 29 ROIs being located in cortical areas (49% of all pathological ROIs). None of the ROIs with impaired perfusion was categorized as "no perfusion", whereas the rest was categorized as "delayed perfusion".

10.1371/journal.pone.0220171.t002

###### Perfusion imaging values of patients 8, 9, and 22, eligible for LowMiR imaging.
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  Patient              8       9       22                                                                                                                                                                         
  -------------------- ------- ------- -------- ------ ------ --------- ------- ------- ------ ------- ------- ------ ------- ------ ------ ------ ------- ------ ------- ------- ------ -------- ------- ------- ------
  **reference**                                                                                                                                                                                                   
  ipT                  23,72   31,20   128,00   0,30   3,33   426,67    17,74   26,78   7,35   16,97   21,57   0,60   13,24   0,08   0,05   7,22   9,41    1,03   0,67    0,94    1,06   0,63     10,06   40,65   4,85
  iaT                  23,03   28,18   40,00    0,34   2,94   117,65    19,04   28,51   8,35   15,65   20,68   0,49   1,93    0,52   0,25   8,53   15,06   2,19   na      na                      10,44   22,35   5,57
  iLN                  22,89   26,42   160,00   0,12   8,33   1333,33   4,96    22,54   2,05   na      22,16   1,31   14,50   0,07   0,09   7,79   9,50    1,28   0,61    0,59    1,69   0,36     7,60    19,85   2,44
  iCN                  22,23   26,19   16,00    0,23   4,35   69,57     4,58    24,48   1,46   na      21,49   0,89   2,36    0,42   0,38   7,44   16,45   1,59   na      na                      10,55   40,97   5,91
  mean                 22,97   28,00                                                           16,31   21,48                                                                                                      
  SD                   0,53    2,00                                                            0,66    0,53                                                                                                       
  median               22,96   27,30                                                           16,31   21,53                                                                                                      
  first quartile       22,73   26,36                                                           15,98   21,29                                                                                                      
  3rd quartile         23,20   28,94                                                           16,64   21,72                                                                                                      
  quartile deviation   0,24    1,29                                                            0,33    0,22                                                                                                       
  **affected**                                                                                                                                                                                                    
  cCN                  25,92   27,59   17,22    1,09   0,92   15,80     4,96    28,02   2,18   na      15,62   0,42   1,83    0,55   0,23   3,43   2,38    0,30   4,40    9,10    0,11   40,04    9,34    43,50   3,00
  caT                  21,67   28,24   52,39    1,38   0,72   37,96     8,21    38,83   6,24   16,40   21,55   4,02   5,56    0,18   0,72   0,73   14,44   1,81   3,41    9,70    0,10   33,08    9,60    28,43   4,02
  cpT                  24,74   28,18   303,64   3,29   0,30   92,29     10,33   24,46   4,41   16,80   21,73   0,94   0,81    1,23   1,16   8,11   19,11   2,43   8,45    18,02   0,06   152,27   8,75    22,38   2,87
  cLN                  24,38   29,44   41,31    1,12   0,89   36,88     7,74    18,23   2,05   12,15   26,13   6,68   3,71    0,27   1,80   6,53   0,82    5,12   16,56   11,22   0,09   185,80   8,84    21,08   2,87
  cWMa                 26,92   64,83   0,18     12,8   0,08   0,01      20,04   10,72   2,46   np      32,48   0,34   3,12    0,32   0,11   6,80   4,35    0,51   50,31   11,74   0,09   590,64   7,01    19,84   4,25
  cWMm                 np      60,70   0,01     0,26   3,85   0,04      11,66   3,79    0,90   np      28,66   3,84   15,60   0,06   0,25   7,36   3,80    0,44   28,11   10,25   0,10   288,13   8,70    33,42   4,24
  cWMp                 np      58,38   1,63     28,2   0,04   0,06      15,18   6,46    1,76   np      32,24   2,80   90,68   0,01   0,03   7,86   8,42    1,21   18,33   43,30   0,02   793,69   7,80    30,19   3,74
  cCora                np      76,25   x        x      x      x         15,89   3,85    1,24   np      29,11   x      x       x      x      8,51   8,05    1,18   x       x       x      x        8,24    22,55   3,00
  cCorm                np      63,31   x        x      x      x         11,19   6,77    1,13   np      25,26   x      x       x      x      7,36   3,80    0,44   x       x       x      x        6,35    16,52   2,13
  cCorp                np      57,66   x        x      x      x         17,10   8,63    2,50   np      31,89   x      x       x      x      7,46   12,59   1,60   x       x       x      x        6,59    19,84   2,47

HighMiB = high mechanical index bolus approach; MRP = magnetic resonance perfusion imaging; LowMiR = low mechanical index refill approach; TTP = time to peak intensity; A = A value; β = β value; MTT = mean transit time; CBF = cerebral blood flow; CBV = cerebral blood volume; ipT = ipsilateral posterior thalamus; iaT = ipsilateral anterior thalamus; iLN = ipsilateral lentiform nucleus; iCN = ipsilateral caudate nucleus; cCN = contralateral caudate nucleus; caT = contralateral anterior thalamus; cpT = contralateral posterior thalamus; cLN = contralateral lentiform nucleus; cWMa = contralateral anterior white matter; cWMm = contralateral middle white matter; cWMp = contralateral posterior white matter; cCora = contralateral anterior cortical area; cCorm = contralateral middle cortical area; cCorp = contralateral posterior cortical area.

10.1371/journal.pone.0220171.t003

###### Perfusion imaging values of patients 23, 25, and 28, eligible for LowMiR imaging.
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  Patient              23       25      28                                                                                                                                                                           
  -------------------- -------- ------- ------ -------- ------ ------- ------ ------- ------- ------- ------- ------ -------- ------- -------- ------- ------- ------- ------- ------ ------ ------- ------- ------- ------
  **reference**                                                                                                                                                                                                      
  ipT                  14,89    1,77    0,56   8,41     6,14   18,15   1,53   31,18   28,07   79,00   0,51    1,96   154,90   2,19    31,18    1,61    19,45   23,12   2,99    2,95   0,34   1,01    2,13    19,27   1,51
  iaT                  15,85    2,31    0,43   6,86     6,23   14,30   2,60   30,48   28,19   29,63   1,43    0,70   20,72    10,87   104,76   19,14   19,65   23,52   2,08    5,87   0,17   0,35    5,92    38,89   3,10
  iLN                  46,59    1,28    0,78   36,40    5,42   15,40   1,53   29,97   27,09   54,00   0,99    1,01   54,55    1,16    28,82    0,65    20,03   23,44   26,43   0,87   1,15   30,38   11,38   16,49   1,39
  iCN                  33,51    2,47    0,40   13,57    6,38   17,94   2,00   29,29   26,82   9,04    19,13   0,05   0,47     3,68    35,16    1,99    19,69   22,62   2,02    4,14   0,24   0,49    6,08    20,97   1,68
  mean                                                                        30,23   27,54                                                            19,71   23,18                                                 
  SD                                                                          0,69    0,60                                                             0,21    0,35                                                  
  median                                                                      30,23   27,58                                                            19,67   23,28                                                 
  first quartile                                                              29,80   27,02                                                            19,60   23,00                                                 
  3rd quartile                                                                30,66   28,10                                                            19,78   23,46                                                 
  quartile deviation                                                          0,43    0,54                                                             0,09    0,23                                                  
  **affected**                                                                                                                                                                                                       
  cCN                  174,00   4,00    0,25   43,50    6,46   21,70   2,00   31,86   27,26   1,34    1,04    0,96   1,29     2,10    48,67    1,67    20,11   22,50   13,45   1,79   0,56   7,51    8,51    17,38   1,69
  caT                  33,50    2,10    0,48   15,95    5,76   13,40   3,64   32,24   27,83   5,58    0,21    4,76   26,57    10,73   65,91    11,37   20,01   23,97   3,72    0,67   1,49   5,55    4,53    39,08   2,81
  cpT                  35,70    2,40    0,42   14,88    7,47   29,27   3,64   31,72   28,38   11,09   2,30    0,43   4,82     6,19    32,26    3,08    22,29   23,54   1,10    1,39   0,72   0,79    2,29    24,31   2,10
  cLN                  62,00    2,30    0,43   26,96    7,32   21,56   2,49   31,52   27,59   11,26   1,53    0,65   7,36     4,17    51,11    3,43    20,05   22,47   2,35    1,07   0,93   2,20    8,17    16,62   1,54
  cWMa                 51,62    0,28    3,57   184,36   6,44   18,22   1,91   29,43   27,56   0,24    7,71    0,13   0,03     1,54    45,31    1,48    20,41   22,85   9,96    0,11   9,09   90,55   5,36    35,30   2,62
  cWMm                 32,44    1,38    0,72   23,51    4,30   19,19   1,63   31,70   29,14   11,74   1,75    0,57   6,71     4,02    33,74    1,69    19,49   23,04   5,42    0,17   5,88   31,88   5,90    23,27   1,89
  cWMp                 29,35    10,57   0,09   2,78     6,23   9,92    1,03   32,58   38,87   0,22    1,08    0,93   0,20     6,00    49,59    4,26    22,23   22,92   5,40    0,38   2,63   14,21   4,70    29,92   2,35
  cCora                x        x       x      x        6,78   15,33   1,45   30,80   27,50   x       x       x      x        1,97    34,74    1,32    20,51   22,67   x       x      x      x       4,40    36,90   2,63
  cCorm                x        x       x      x        7,60   15,69   1,91   36,80   28,71   x       x       x      x        4,88    27,11    2,34    19,61   23,37   x       x      x      x       2,68    19,78   1,71
  cCorp                x        x       x      x        5,07   18,23   1,50   33,60   37,09   x       x       x      x        10,90   69,02    10,06   18,81   23,41   x       x      x      x       5,21    31,28   2,33

10.1371/journal.pone.0220171.t004

###### Perfusion imaging values of patients 31 and 12, eligible for LowMiR imaging.
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  Patient              31      12                                                                                                                               
  -------------------- ------- ------- ------ ------- ------ ------ ------- ------- ------ ------- ------- -------- -------- -------- -------- ------- -------- ------
  **reference**                                                                                                                                                 
  ipT                  27,81   30,97   0,78   17,65   0,06   0,04   1,24    20,17   0,47   21,73   26,61   no TIC   no TIC   no TIC   no TIC   2,32    128,80   5,74
  iaT                  26,73   30,43   0,74   25,21   0,04   0,03   3,35    26,33   1,49   22,85   27,24   no TIC   no TIC   no TIC   no TIC   3,05    137,99   7,26
  iLN                  26,57   31,22   4,37   6,30    0,16   0,69   5,82    7,37    0,88   20,89   22,91   no TIC   no TIC   no TIC   no TIC   1,33    70,10    2,40
  iCN                  25,97   31,16   1,51   8,92    0,11   0,17   11,62   13,22   2,03   20,21   26,61   no TIC   no TIC   no TIC   no TIC   2,96    89,41    4,86
  mean                 26,77   30,95                                                       21,42   25,84                                                        
  SD                   0,66    0,31                                                        0,99    1,71                                                         
  median               26,65   31,07                                                       21,31   26,61                                                        
  first quartile       26,42   30,84                                                       20,72   25,69                                                        
  3rd quartile         27,00   31,18                                                       22,01   26,77                                                        
  quartile deviation   0,29    0,17                                                        0,65    0,54                                                         
  **affected**                                                                                                                                                  
  cCN                  27,69   32,10   0,55   92,75   0,01   0,01   11,51   14,86   3,32   na      28,20   3,10     0,30     3,33     0,93     3,36    42,84    3,26
  caT                  27,53   29,91   1,78   9,46    0,11   0,19   2,98    12,47   0,88   21,45   30,77   13,51    1,59     0,63     21,48    3,11    93,09    4,81
  cpT                  28,87   31,01   1,57   8,76    0,11   0,18   0,00    13,17   0,00   24,11   30,39   33,61    3,14     0,32     105,54   2,49    81,61    4,86
  cLN                  28,23   24,87   3,80   1,05    0,95   3,62   0,03    7,74    0,00   np      42,63   40,08    5,79     0,17     232,06   1,90    13,81    0,44
  cWMa                 27,63   34,78   3,26   5,72    0,17   0,57   5,77    16,23   1,75   np      50,05   0,82     39,62    0,03     32,49    11,06   15,19    2,67
  cWMm                 29,79   44,69   4,16   23,98   0,04   0,17   17,69   11,14   3,13   21,50   33,11   16,25    1,82     0,55     29,58    2,48    54,18    2,98
  cWMp                 30,70   47,08   3,22   3,26    0,31   0,99   10,04   14,57   2,89   18,19   32,53   5,70     4,50     0,22     25,65    5,30    99,61    7,01
  cCora                33,60   35,67   x      x       x      x      7,28    21,53   4,02   np      30,26   x        x        x        x        4,66    75,91    5,35
  cCorm                31,84   50,02   x      x       x      x      17,25   15,63   4,18   np      34,50   x        x        x        x        5,48    40,55    4,11
  cCorp                29,70   49,54   x      x       x      x      19,50   12,16   4,02   25,41   34,17   x        x        x        x        4,08    52,93    4,16

Perfusion deficits as defined by UPI {#sec014}
------------------------------------

For data values of UPI imaging modalities see Figs [2](#pone.0220171.g002){ref-type="fig"} and [3](#pone.0220171.g003){ref-type="fig"}, as well as Tables [5](#pone.0220171.t005){ref-type="table"}--[7](#pone.0220171.t007){ref-type="table"}. LowMiR analyses displayed a wide range of A, ß, and Axß. Statistical analyses using linear regression analyses revealed poor correlation of ß to rCBV (of MRI/CT perfusion imaging) and of Axß to rCBF in areas categorized as "delayed" or "non-perfused" as seen in [Fig 2](#pone.0220171.g002){ref-type="fig"}. ROC analyses of HighMiB TPI values have formerly shown high sensitivity of ultrasound perfusion imaging in the diagnosis of hypo-perfused area under the curve, (AUC = 0.917; p\<0.001) and nonperfused (AUC = 0.830; p\<0.001) tissue in comparison with MRP/CTP \[[@pone.0220171.ref004]\]. Here, we analyzed the correlation of the TPI / TTP delay of HighMiB and CTP/MRP, respectively, also using scatter plot revealing linear correlation as seen in [Fig 3](#pone.0220171.g003){ref-type="fig"}. Bland Altman plot showed the correlation between analyzes done with HighMiB versus MRP / CTP ([Fig 4](#pone.0220171.g004){ref-type="fig"}). Differences for TTP measured by HighMI in comparison to MRP/ CTP examinations were on average -1.36±0.71, resulting in a coefficient of repeatability of 16.87. By trying to apply the Bland Altman test for the ß versus rCBV or Axß versus rCBF analyses, the difference between the values proved to be significant, so that these values cannot show a level of agreement and a Bland-Altman test was not feasible. Indirect comparison of the diagnostic accuracy in the six patients with both UPI modalities (i.e., LowMiR vs. HighMiB) displayed a PPV and NPV values as displayed in Tables [3](#pone.0220171.t003){ref-type="table"} to [5](#pone.0220171.t005){ref-type="table"}.

10.1371/journal.pone.0220171.t005

###### Four-fold table for the analysis of PPV and NPV of HighMiB TTP in comparison to CTP/MRP.
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  TTP                    CTP/MRP positive   CTP/MRP negative
  ---------------------- ------------------ ------------------
  **HighMiB positive**   8                  0
  **HighMiB negative**   4                  48

PPV and NPV values of ROIs categorized as positive by HighMiB TTP \>3 s in comparison to CTP/MRP defined positive with a pathological perfusion (TTP \>4 s) in 66 ROIs. Note that cortical ROIs were not included and that in six ROIs HighMiB analyses were not applicable. PPV = 1. NPV = .92

10.1371/journal.pone.0220171.t006

###### Four-fold table for the analysis of PPV and NPV of LowMiR β in comparison to CTP/MRP.
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  Β                     CTP/MRP positive   CTP/MRP negative
  --------------------- ------------------ ------------------
  **LowMiR positive**   0                  39
  **LowMiR negative**   0                  23

PPV and NPV values of ROIs categorized as positive by LowMiR β \<0.76 in comparison to CTP/MRP defined positive with a pathological perfusion (TTP \>4 s) in 66 ROIs. Note that cortical ROIs were not included and that in 4 ROIs LowMiR analyses were not applicable. PPV = 0. NPV = 1

10.1371/journal.pone.0220171.t007

###### Four-fold table for the analysis of PPV and NPV of LowMiR Axβ in comparison to CTP/MRP.
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  Axβ                   CTP/MRP positive   CTP/MRP negative
  --------------------- ------------------ ------------------
  **LowMiR positive**   6                  28
  **LowMiR negative**   2                  26

PPV and NPV values of ROIs categorized as positive by LowMiR Axβ \<1.91 in comparison to CTP/MRP defined positive with a pathological perfusion (TTP \>4 s) in 66 ROIs. Note that cortical ROIs were not included and that in 4 ROIs LowMiR analyses were not applicable. PPV = .18. NPV = .63

![Scatter plot for correlation between LowMiR and CT/MRI rCBF.\
Scatter plot showing a poor correlation between Axβ (a) and β (b) values measured by LowMiR UPI versus perfusion CT/MRI rCBF (a) and rCBV (b). R^2^ coefficient of determination is 0.001 (a) and 0.009 (b), respectively.](pone.0220171.g002){#pone.0220171.g002}

![Scatter plot for correlation between HighMiB and CT/MRI TTP values.\
Scatter plot showing the linear correlation between absolute TTP delay values measured by HighMiB UPI versus perfusion CT/MRI. R^2^ coefficient of determination is 0.159.](pone.0220171.g003){#pone.0220171.g003}

![Bland Altman plot for mean of TTP values as measured by HighMiB Investigation in comparison to MRP/CTP.](pone.0220171.g004){#pone.0220171.g004}

Discussion {#sec015}
==========

UPI is a technique of micro-vascular, parenchymal imaging that has been introduced in the late 1990s. Different ultrasound techniques and modalities of data acquisition have since been validated \[[@pone.0220171.ref001],[@pone.0220171.ref009],[@pone.0220171.ref010]\]. Since CT perfusion imaging has since been widely established as a standard imaging technique, the potential advantages of mobility and easy repeatability of ultrasound imaging have been lost sight of in acute stroke imaging. Using the so-called bilateral approach with the affected hemisphere in the far field, the non-affected hemisphere can be used as an intra-individual reference for specific parameters (such as the TTP) with the bolus-kinetics approach. Hereby, areas of the basal ganglia, white matter, and cortical regions can be evaluated \[[@pone.0220171.ref002],[@pone.0220171.ref004]\]. Due to the settings used in low MI imaging, insonation parameters only enable evaluation up to a depth of about 10 cm. Therefore, low MI imaging has technically to be performed from the affected side (unilateral approach); hence, those structures closest to the probe (cortical areas), are lost for evaluation due to well-known technical near-field artifacts (compare [Fig 5](#pone.0220171.g005){ref-type="fig"}). In our series of consecutive stroke patients, the considerable amount of 49% of the affected ROIs (as defined by MRP/CTP) were located in cortical areas, which can be attributed to the expected rate of territorial ischemia due to middle cerebral artery occlusion in a series of acute stroke. HighMiB, performed from the side of the unaffected hemisphere, can evaluate these ROIs with good correlation to MRP or CTP \[[@pone.0220171.ref004]\]. However, HighMiB examinations are limited to one plane of insonation per time. In bolus tracking, a certain amount of time (of about 15--20 min) is necessary for the bolus to "decay" before the next examination can be taken. The refill-kinetic approach, on the other hand, enables numerous examinations in various planes of insonation \[[@pone.0220171.ref007]\]. Since the contrast agent in the blood pool practically stays saturated after infusion of the contrast agent for some minutes, multiple examinations in several planes are possible in a certain time frame. Therefore, this approach has also been termed as a "real-time" examination. Since the discrimination of the ischemic core of infarction from functionally impaired hypo-perfused tissue (penumbra) is of special interest in acute stroke (e.g., once considering revascularizing therapies), a comparison of both methods in "real life" under clinical settings is of substantial interest and therefore challenged here. If the examination quality were the same between methods, the "real-time" aspect would be, indeed, an advantage.

![Parameter maps of perfusion imaging in patient 8 (occlusion of M1 branch of MCA).\
(a): MRP-TPI parameter map displaying perfusion deficit in \>2/3 of the right MCA territory; (b): HighMiB-TPI parameter map tilted in accordance to MRP orientation taken from the side contralateral to the expected perfusion lesion displaying a perfusion deficit in the according area; (c): LowMiR-rCBV parameter maps taken from both sides and tilted/overlaid according to MRP orientation displaying the restricted depth of insonation (evaluation restricted to the hemisphere close to the probe) and the restricted area of possible quantification due to the near filed artifacts in the non-affected hemisphere.](pone.0220171.g005){#pone.0220171.g005}

However, in our series we found some substantial drawbacks of both methods. Only in 18 out of 31 patients consecutively included, any UPI method displayed evaluable data. This may be attributable to a great extent to the emergency setting in the angio-suite just before interventional therapy. Therefore, the main result of our study is that UPI using current techniques cannot be regarded as a sufficient diagnostic tool in an emergency setting despite its´ inherent advantages of mobility as a bed-site technique. LowMiR displayed evaluable data in only half of the patients in which HighMiB was possible. Furthermore, quantification of perfusion parameters was not as satisfactory as might have been expected from the literature. Kern and colleagues \[[@pone.0220171.ref007]\] found semi-quantitative perfusion parameters in their collective (up to **48 hrs** after symptom onset, though) using the LowMiR approach. The β value (as a parameter of rise rate or rCBV) was found to be diminished in the area of stroke, the mean β ratio ischemic/normal was 0.48. The product of Axβ (as a function of rCBF) and A (as a parameter of plateau) were lower in ischemia. A good correlation was only found between the ischemic and normal hemispheres; however, the only form of quantification was possible using the rtTTP (i.e. bolus-kinetics using a low MI with above mentioned restricted depth of examination). Furthermore, ROIs were placed in the affected hemisphere without standardized size and localization. In our collective, we were able to reproduce the insufficient nature of cerebral perfusion quantification using the low MI refill-kinetics approach. At the same time, high MI bolus tracking proved to consistently well reproduce perfusion impairments as displayed by golden standard MRP or CTP.

LowMiR using refill-kinetics potentially has the advantage of real time (multi-plane) imaging and better resolution, whereas it has previously been discussed that HighMiB has the disadvantage of a so-called shadowing effect, implying that due to the burst of destructed microbubbles the areas further from the probe should not be evaluable. In this trial, however, we were able to show in accordance to former studies, that the HighMiB approach is capable of detecting perfusion deficits throughout both hemispheres. Furthermore, technical progress will allow multidimensional data acquisition in the near future, so that bolus tracking will also be possible in a multi-plane manner. Thus, if quantification is mandatory, the high MI bolus approach delivers more robust data.

There are some further limitations to this unblinded study, the most striking one is the small sample size as mentioned above. For direct comparison of the two approaches, data of only 6 patients could be used. This is partly due to the strikingly high number of technically unsuccessful examinations using the low MI approach. Only in 8/20 patients the LowMiR exam was technically successful, whereas in 16/20 patients HighMiB exams displayed evaluable data. Statistical analysis and conclusions are limited due to the small amount of only 6 patients evaluable for direct comparison of the two methods. However, within these six patients, 66 ROIs were used for analysis, because of which statistical analyses were performed as described. Another limitation is the heterogeneous character of our cohort. All patients with a reported MCA occlusion were included, resulting in a range of patients with a distal carotid T- and M1 occlusion up to patients with a M3/4 branch occlusion in final angiography. Furthermore, comparisons of both UPI techniques were drawn to either CT- or MR-perfusion, somewhat impeding the congruency of the results. However, the study was designed to proof the principle feasibility of ultrasound perfusion imaging in the complex situation of acute diagnosis and treatment in stroke patients, and, therefore, heterogeneous vessel and perfusion pathology was rather aimed for.

Conclusion {#sec016}
==========

Ultrasound imaging inherits the advantage of mobile application and could, therefore, theoretically be used in a preclinical setting as an additional multimodal diagnostic tool to guide early stroke treatment, detecting occlusion of large vessels \[[@pone.0220171.ref011]\], ruling out intracerebral hemorrhage \[[@pone.0220171.ref012]\], and displaying parenchymal perfusion status. It has not yet been proven which of the established perfusion approaches would serve best. In this small series, HighMiB proves the higher potential for differentiating ischemic and hypoperfuzed tissue both with respect to imaging quality and semi-quantitative evaluation. Therefore, the potential of multimodal ultrasound imaging using high MI bolus tracking should now be tested in a larger series in a blinded and multicenter approach. For the time being, with all limitations seen in the emergency setting this study, UPI might serve as a potential diagnostic tool for early follow up examinations in patients undergoing revascularizing therapies in ischemic stroke.

Supporting information {#sec017}
======================

###### Dataset of Tables [2](#pone.0220171.t002){ref-type="table"}--[4](#pone.0220171.t004){ref-type="table"} containing all original data concerning the direct comparison of the two UPI groups.

(XLSX)

###### 

Click here for additional data file.

###### Containing data of HighMiB examinations of those patients where LowMiB was not successful for direct comparison (patients 1,3,4,6,7,15,17,20,24).

(XLSX)

###### 

Click here for additional data file.
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